Table 1. Therapeutic effects of the administration of recombinant human pPAF-AH in human sepsis patients and mouse models.

	Status	Year	Effect	Reference
Human	Phase IIa	1999	Improvements in oxygenation and multiple organ dysfunction	[20]
	Phase IIb	2003	Striking survival advantage and other positive effects	[21]
	Phase III	2004	No effect on decreasing mortality	[22]
Mouse	LPS/CLP model	2006	Reduction of inflammatory injury and mortality	[9]

Mouse represented the C57BL/6 mouse.